Page 5 - அமெரிக்கன் சங்கம் ஆஃப் புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

OrbiMed-incubated Theseus unveils $100M to beat cancer drug resistance OrbiMed-incubated Theseus unveils $100M to beat cancer drug resistance Incubated by OribMed and led by Ariad Pharmaceuticals veterans, Theseus Pharmaceuticals unveiled $100 million in Series B financing to develop the next generation of tyrosine kinase inhibitors, a type of cancer drug. The company expects to enter the clinic by the end of 2021. Shares0   One of the challenges of treating cancer is the ability of cancer cells to mutate, which leads to resistance to currently available therapies. Theseus Pharmaceuticals has spent the past two years quietly developing a way to overcome this drug resistance and it picked one of the biggest cancer conferences of the year to unveil its technology, along with $100 million funding, as it looks ahead to clinical trials.

United statesUnited kingdomTheseus pharmaceuticalsAriad pharmaceuticalsAmerican association of cancer researchAmerican associationCancer researchTakeda pharmaceuticalAdage capital managementBoxer capitalFarallon capital managementLongitude capitalNextech venturesOmega healthcare investorsPontifax venture capitalRock springs capital